| Global Research Trends

Friday, 2 April 2021

Transthyretin Amyloidosis Treatment Market Opportunity Analysis - 2026

The Global Transthyretin Amyloidosis Treatment Market, by Drug Type (Tafamidis (Vyndaqel), Patisiran (ONPATTRO), Inotersen (TEGSEDI), and Others), by Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild Type), and by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Geography (North America, Latin America, Europe, Asia-Pacific, Middle East and Africa) is expected to be valued at US$ 35.8 million in 2018 and is projected to exhibit a CAGR of 55.4% over the forecast period (2018–2026).

Launch of novel therapies indicated for the treatment of transthyretin amyloidosis is expected to propel growth of the market. For instance, in October 2018, Alnylam Pharmaceuticals, Inc. launched ONPATTRO (patisiran) in Germany. The drug is indicated for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. In October 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) approval for its novel drug TEGSEDI (inotersen) indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Key manufacturers in market have their novel therapies under development pipeline and are expected to gain approval in the near future. Presence of robust pipeline is also expected to be one the major factors driving the market growth. For instance, in March 2018, Pfizer, Inc. reported positive results from Phase 3 ATTR-ACT study of Tafamidis among patients suffering from transthyretin cardiomyopathy

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/687

Browse 35 Market Data Tables and 43 Figures spread through 221 Pages and in-depth TOC on Global Transthyretin Amyloidosis Treatment Market, by Drug Type (Tafamidis (Vyndaqel), Patisiran (ONPATTRO), Inotersen (TEGSEDI), and Others), by Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild Type), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Forecast to 2026

Key players in the market are focused on strategic mergers and partnerships in order to enhance their market share. For instance, In October 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. entered into distribution agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts to distribute TEGSEDI (inotersen) subcutaneous injection for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. In August 2018, Alnylam Pharmaceuticals, Inc. partnered with US Bioservices, a specialty pharmacy and part of AmerisourceBergen, to dispense ONPATTRO (patisiran) lipid complex injection.

Transthyretin amyloidosis is a rare disease and its symptoms are not easily identified. It is therefore, diagnosed late, which in turn affects the course of action in terms of treatment. According to the data published by The American Journal of Managed Care in 2017, hereditary transthyretin-mediated (hATTR) amyloidosis affects around 50,000 patients worldwide. However, the diagnosis rate of disease is very low. According to the study published by Alnylam Pharmaceuticals, Inc., in January 2018, the diagnosis rate of hATTR in the U.S. is around ~10-30%, which is expected to be a major factor restraining growth of the market over the forecast period.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/transthyretin-amyloidosis-treatment-market-687

Key Takeaways of the Global Transthyretin Amyloidosis Treatment Market:

The global transthyretin amyloidosis treatment market is expected to exhibit a CAGR of 4% over the forecast period, owing to product launches by manufacturers such as Alnylam Pharmaceuticals, Inc. and Ionis Therapeutics

North America is expected to hold dominant position in the global transthyretin amyloidosis treatment market over the forecast period, owing to approval and launch of new products in the region. For instance, in June 2017, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Pfizer Inc.’s Tafamidis, the company’s investigational treatment therapy for Transthyretin Cardiomyopathy (TTR-CM).

Asia Pacific is expected to witness significant growth in the market due increasing approvals of novel therapies in the region. For instance, in March, 2018, the Ministry of Health Labor and Welfare in Japan granted SAKIGAKE designation to Pfizer Inc.’s Tafamidis, for the treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

However, no approved drugs are available for the treatment of cardiomyopathy. Therefore, key players in the market are could focus on this opportunity to receive approval for their drugs for cardiomyopathy indication and can launch their drug in key region such as the U.S. to enhance their market share.

Similar to cardiomyopathy, no specifically approved drug is available for the treatment of wild-type transthyretin amyloidosis. Therefore, key players could focus on this opportunity to develop drugs for the treatment of wild type disease to gain high revenue and market share.

Major players operating in the global transthyretin amyloidosis treatment market include, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/687

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-173

Preimplantation Genetic Diagnosis Market Size Share Trends Forecast 2027

Preimplantation genetic diagnosis is used for a broader range of indications, including chromosomal abnormalities, genetic abnormalities associated with adult onset disorders, rhesus incompatibility, human leukocyte antigens (HLA) tissue type, and intentionally selecting for medical conditions (deafness) and traits like sex.

Statistics:

The global Preimplantation Genetic Diagnosis Market is estimated to account for US$ 53.5 Mn in terms of value in 2020 and is expected to reach US$ 81.6 Mn by the end of 2027.

Global Preimplantation Genetic Diagnosis Market: Drivers

Rising rate of infertility is expected to propel growth of the global preimplantation genetic diagnosis market over the forecast period. For instance, according to the National Survey of Family Growth data published in September 2018, 15.5% of all women who intend to become pregnant are infertile and 6.7% of married women aged 15 to 44 years are infertile, in the U.S.

Global Preimplantation Genetic Diagnosis Market: Opportunities

R&D in genetics is expected to offer lucrative growth opportunities for players in the global preimplantation genetic diagnosis market. People want to be guilt free from giving the sufferings of genetic disorders to their children. Clinical progress in the IVF and preimplantation genetic diagnosis and the increasing knowledge in the medicine and molecular field associated with both male and female infertility and that in intracytoplasmic sperm injection will assist in growth of the global preimplantation genetic diagnosis market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/698

Global Preimplantation Genetic Diagnosis Market: Restraints

Scientific, ethical, and policy issues are expected to hinder growth of the global preimplantation genetic diagnosis market. There are quite a few issues persistent about the safety of the in vitro fertilization in preimplantation genetic diagnosis. The accuracy of these methods is also questioned by a few physicians and researchers. In addition, few people also find preimplantation genetic diagnosis as morally unacceptable because of involvement of unnatural creation and destruction of human embryo. There is a huge ethical issues regarding whether preimplantation genetic diagnosis should be adopted or not.

Key Takeaways:

The global preimplantation genetic diagnosis market was valued at US$ 50.3 Mn in 2019 and is forecast to reach a value of US$ 81.6 Mn by 2027 at a CAGR of 6.2% between 2020 and 2027. Major factor driving the growth of global preimplantation genetic diagnosis market during the forecast period include increasing incidences of genetic diseases, and increasing number of fertility centers.

Chromosomal Abnormalities held dominant position in the global preimplantation genetic diagnosis market in 2019, accounting for 20.1% share in terms of value, followed by X-linked diseases and Aneuploidy, respectively. Increasing prevalence of genetic disorders is supporting growth of the segment.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/preimplantation-genetic-diagnosis-market-698

Market Trends

Major players in the global preimplantation genetic diagnosis market are focused on adopting partnership and collaboration strategies to enhance their market share. For instance, in October 2018, Illumina Inc. signed an agreement with Vitrolife AB under which Vitrolife act as a distributor supplier of Illumina’s PGT products in EMEA and America.

Major players in the global preimplantation genetic diagnosis market are also focused on adopting expansion strategies to enhance their market share. For instance, in June 2020, Natera, Inc. announced the expansion of its laboratory facility in Austin, Texas, supporting greater test processing capacity.

Global Preimplantation Genetic Diagnosis Market: Competitive Landscape

Major players operating in the global preimplantation genetic diagnosis include, Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.

Global Preimplantation Genetic Diagnosis Market: Key Developments

Major players in the global preimplantation genetic diagnosis market are focused on adopting various strategies to enhance their market share. For instance, in April 2019, Quest Diagnostics presented new insights from genetic testing at the 2019 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, held in the U.S.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/698

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-173

Contact Lens Market To Reach US$ 29,934.2 Million By 2027 - Coherent Market Insights

Contact lenses can be primarily segmented as hard contact lenses and soft contact lenses. Hard contact lenses are made of stiff plastic, while soft contact lenses are made up of silicone hydrogel. These lenses are produced in various designs such as multifocal, spherical, toric and orthokeratology contact lenses.

Statistics:

The global Contact Lens Market is estimated to account for US$ 13,478.5 Mn in terms of value by the end of 2019.

Global Contact Lens Market: Drivers

Approval and launch of new products is expected to propel growth of global contact lens market over the forecast period. For instance, in November 2019, CooperVision received U.S. Food and Drug Administration (FDA) approval for its MiSight 1 day contact lens that is indicated to slow the progression of myopia in children 8-12 years old.

Global Contact Lens Market: Opportunities

Increasing awareness about vision care is expected to offer lucrative growth opportunities for players in the global contact lens market. For instance, in February 2020, Essilor Vision Foundation, through its Vote for Vision campaign, encouraged the populace to get an eye exam in 2020.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/715

Global Contact Lens Market: Restraints

High cost of contact lenses is expected to hinder growth of the global contact lens market. The contact lens market is price sensitive, where high cost of lenses results in a large number of consumers switching to alternate options. Lack of structured regulatory policies has led to high fluctuations in the final pricing of contact lenses, resulting in price wars between existing market players.

Key Takeaways:

The global contact lens market was valued at US$ 13,478.5 Mn in 2019 and is forecast to reach a value of US$ 29,934.2 Mn by 2027 at a CAGR of 10.5% between 2020 and 2027. Approval and launch of new products is expected to propel growth of global contact lens market over the forecast period

Soft Contact Lens segment held dominant position in the global contact lens market in 2019, accounting for 86.5% share in terms of value, increasing awareness about vision care is expected to assist the segment growth

Market Trends

Increasing prevalence of vision impairment is expected to propel demand for contact lenses. For instance, according to World Health Organization (WHO), 2019, globally, at least 2.2 billion people have a vision impairment or blindness, of whom at least 1 billion have a vision impairment that could have been prevented or has yet to be addressed.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/contact-lens-market-715

Major players in the global contact lens market are focused on launching various services to enhance their market share. For instance, in August 2020, Johnson & Johnson Vision released resources to enhance the contact lens experience in terms of comfort, safety and accessibility.

Global Contact Lens Market: Competitive Landscape

Major players operating in the global contact lens market include, Novartis International AG, Menicon Group, The Cooper Companies, Inc., Carl Zeiss AG, Baush and Lomb, Visioneering Technologies, Inc., Mojo Vision, Johnson & Johnson Vision, Air Optix, Essilor, SynergEyes, Inc., Conforma, Menicon, UltraVision, and Wesley Jessen.

Global Contact Lens Market: Key Developments

Major players in the global contact lens market are focused on conducting clinical trials to expand their product portfolio. For instance, in April 2019, Visioneering Technologies, Inc. released additional data regarding its patented NaturalVue Multifocal (etafilcon A) 1 Day Contact Lens.

Major players in the global contact lens market are also focused on product approval and launch to expand their product portfolio. For instance, in January 2019, SynergEyes, Inc. launched SimplifEyes 1 Day daily disposable lens with dual tangible polymers.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/715

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-173

Mesenchymal Stem Cells Market Size, Trends, Shares, Insights and Forecast – 2018-2026

North America and Asia Pacific are expected to hold large Mesenchymal Stem Cells Market shares followed by Europe due to the rapid growth in technological innovations, high disposable incomes, and the well-equipped healthcare centers, which will lead to the growth and development of MSCs market. The implantation of new mesenchymal stem cells in cancer patients is expected to enhance the growth of MSCs market.

As per the World Health Organization (WHO) 2018 Factsheet, Cancer is the second leading cause of death globally, and it caused around 9.6 million deaths in 2018 globally. According to the European Journal of Cancer, Europe witnessed over 3.9 million cases of cancer and around 1.9 million deaths from cancer in the year 2018. Whereas, according to National Center for Biotechnology Information (NCBI), in Asia Pacific, breast cancer in females was found to be around 18.0% in the year 2012 and it was the fourth most cause for around 9% death due to cancer in the region.

Mesenchymal stem cells, also known as Mesenchymal Stromal Cells (MSCs), are adult, fibroblast-like multipotent cells that can differentiate and mature into tissues of mesodermal origin such as adipocytes, chondroblasts, and osteoblasts. Mesenchymal stem cells were isolated first time from the bone marrow and later from various sources such as cord cells, adipose tissue, and molar cells. MSCs in terms of size, are smaller and are quite difficult to observe in histological sections. A group of mesenchymal stem cells are called as mesenchyme and is widely distributed in the body. Mesenchymal cells can multiply in numbers of specialized cells and they can grow in-vitro or in-vivo condition.

The mesenchymal stem cells play an important role within an organism for suppression of immune cells activation, increase the number of newer cells, reduce cell death or cell damage in the body, and secretion of both neurotrophic and angiogenic factors, which are responsible for stabilizing the extracellular matrix, when transplanted to the brain, this cells promote the reduction of free radical levels and enhance synaptic connections of damaged neurons, and increases the myelination of axons. The mesenchymal cells are also able to replace and repair any damaged blood vessel in the cerebrum brain.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/720

Rise in prevalence of osteoporosis and increase in cancer incidences are expected to support the global market growth

MSCs have the ability to grow bone tissues through the bone surface to form new bone, which in turn has the potency to treat osteoporosis. According to the National Institute of Health (NIH), in 2015, the U.S. accounted for around 53 million people suffering from osteoporosis or at a high risk due to low bone mass.

According to Osteoporosis Canada, around 1 in 5 men and 1 in 3 women suffer from osteoporotic fracture during their lifetime, whereas osteoporosis causes around 70-90% of 30,000 hip fractures yearly; the annual cost to Canada for treating osteoporosis was around US$ 4.0 billion in the year 2012, which is expected to rise in the upcoming years. Furthermore, according to the International Osteoporosis Foundation (IOF), annually around 9.0 million people worldwide are suffering from osteoporosis fractures. The aforementioned factors are expected to bolster the Mesenchymal stem cells market growth over the forecast period.

Mesenchymal Stem Cells Market Players

Key players in the market are focusing on inorganic growth strategies such as acquisition and collaboration in order to expand its research and development activities and geographical presence. For instance in February 2019 Pluristem Therapeutics has collaborated with the NASA's Ames Research Center to evaluate the potential of Pluristem's PLX cell therapies in preventing and treating medical conditions caused during space missions.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/mesenchymal-stem-cells-market-720

During space mission astronauts are exposed to a challenging environment that includes radiation and microgravity, leading to muscle and bone loss as well as other potentially serious medical conditions. The collaboration will explore the possibility that PLX placenta-based cell therapy products can address these and other persistent negative effects of space travel on the human body.

In February 2019, BrainStorm Cell Therapeutics Inc. announced to expand its clinical trial facility with Cleveland Clinic as the first U.S. clinical site contracted for a planned Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous Mesenchymal Stem Cell (MSC-NTF) cells in participants with progressive Multiple Sclerosis (MS).

Moreover most of the key players are focusing on new product launch in the global mesenchymal stem cell market. For instance in February 2019, Cytonus Therapeutics has developed Cargocytes a first-of-its-kind, controllable, cell-based platform technology for delivery of biologics. Cargocytes are engineered allogenic cell lines that can carry a variety of small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies and oncolytic viruses. As a platform technology, cargocyte has many therapeutic applications and will be commercialized through a blend of internal and partnered programs.

Some of the key market players identified across the value chain of mesenchymal stem cells market are, Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/720

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-173

Myelofibrosis Treatment Market Size, Share, Outlook, and Opportunity Analysis, 2018– 2026

North America to dominate the market with the rising prevalence of myelofibrosis and favorable reimbursement scenario

Regional segmentation of the global Myelofibrosis Treatment Market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to dominate the global myelofibrosis treatment market owing to the growing public awareness, high prevalence of the disease, favorable reimbursement policies, and a higher percentage of the income spent on healthcare. According to the American Society of Hematology 2016, myelofibrosis is a potentially life-threatening blood cancer that affected approximately 20,000 Americans. Asia Pacific is expected to hold a large share of the global market during the forecast period owing to increased disposable incomes, high geriatric population, and improved healthcare facilities.

Myelofibrosis is a bone marrow disease that interrupts the blood cells production process in the body. Fibrous or scar tissue gets developed in the bone marrow leading to scarring causing insufficient blood cell production. Myelofibrosis is a rare type of chronic leukemia affecting blood production. The symptoms of myelofibrosis include severe anemia, fatigue, weakness, and enlarged spleen. The disease is usually found to occur in individuals over the age of 50 years. Myelofibrosis is of two types namely, primary myelofibrosis and secondary myelofibrosis.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/721

The treatment options are scarce but the U.S. Food and Drug Administration (FDA) approved Jakafi (Ruxolitinib) in 2011, a drug developed by Novartis, which is the only approved product for the treatment of myelofibrosis that forms a major line of defense against the disease.

Increase in FDA approval of pipeline drugs is expected to drive the market

Growing prevalence of myelofibrosis in developing economies drives the demand for various treatment options for myelofibrosis. The market is expected to grow owing to heavy investments in research and development, appropriate reimbursement conditions, and a large pool of patients living with myelofibrosis. In addition, the market growth can be attributed to other factors including lifestyle up-gradation, unmet medical needs of the patients, increasing incidences of genetic disorders, and escalating smoking population. The market is expected to gain significant traction with the medical advancements focusing patients suffering from myelofibrosis. For instance, development of a molecule, CYT387 or Momelotinib, by Gilead Sciences for treating primary myelofibrosis and the innovation of current drug, ruxolitinib, by Incyte Corporation to develop a substitute dosing strategy in patients with myelofibrosis.

However, limited awareness of the novel therapies and high costs involved in treatment are the factors restricting the growth of the global myelofibrosis treatment market.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/myelofibrosis-treatment-market-721

Myelofibrosis Treatment Market Taxonomy

The global myelofibrosis treatment market is segmented on the basis of diagnosis, treatment, end user, and geography.

Pipeline drug, Pacritinib, developed by Biopharma reveals higher therapeutic efficacy for myelofibrosis treatment

The key players operating in the global myelofibrosis treatment market include Novartis, Eli Lilly, Roche, Merck & Co., Celgene, Amgen, Bristol-Myers Squibb, Incyte Corporation, and Gilead Sciences. The key players are focused on developing effective treatments that are aimed at easing the patient symptoms with fewer side effects and improving the quality of life. For instance, Biopharma developed Pacritinib in 2016, which is proven to be more effective through the clinical trials than the FDA approved ruxolitinib.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/721

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-173

Thursday, 1 April 2021

Patient Flow Management Solutions Market Size Share Trends Forecast 2026

The Global Patient Flow Management Solutions Market, by Product Type (Integrated and Standalone), by Component (Hardware, Software, and Services), by Delivery Mode (Web-based/Cloud-based and On-premise), by End User (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 539.1 million in 2018, and is projected to exhibit a CAGR of 18.8% during the forecast period (2018 – 2026).

Key players in the market are engaged in improving their in-house patient flow management solutions by collaborating and partnering with new key players in the market. For instance, in May 2018, Change Healthcare (a joint venture of McKesson Corporation and Change Healthcare Holdings, Inc.) announced plans to collaborate with Adobe and Microsoft. Together, the companies will develop a cloud-based tool that can aggregate and activate consumer data from disparate sources such as electronic health records (EHRs), patient registration, scheduling, and billing, among others. In July 2018, Change Healthcare received the US$ 5.5 million grant from The Israel Innovation Authority (IIA), to expand its research and development (R&D) facility in Israel. In September 2018, Hyland Healthcare and Change Healthcare partnered to offer fully integrated medical claims attachment technology. This allows providers and payers to transmit claims attachment quickly and improves patient experience, optimize the revenue cycle, and reduce inefficiency and wait time.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/730

Browse 25 Market Data Tables and 29 Figures spread through 183 Pages and in-depth TOC on ‘Patient Flow Management Solutions Market, by Product Type (Integrated and Standalone), by Component (Hardware, Software, and Services), by Delivery Mode (Web-based/Cloud-based and On-premise), by End User (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026’

Furthermore, key players in the market are focused on acquisition strategies to expand their geographical presence. For instance, in October 2015, Aptean completed the acquisition of Medworxx Solutions Inc. Through the acquisition, Medworxx’s knowledge management, patient flow, and patient safety solutions portfolio for healthcare organizations was added to Aptean’s product portfolio. In May 2018, Allscripts Healthcare Solutions signed a definitive agreement to acquire HealthGrid Holding Company. HealthGrid is a developer of mobile patient engagement platforms, which enable providers to reach patients using existing contact information, without requiring them to sign up for a patient portal. Furthermore, under the agreement, Allscripts will integrate HealthGrid's functions into its FollowMyHealth patient engagement platform. In June 2017, Aptean acquired FDM Software. This acquisition enables Aptean to offer an integrated platform with hospital patient flow capabilities. FDM Software operates its business in Records Management (RMS), Computer-Aided Dispatch (CAD), mapping and analysis solutions for public safety agencies in North America and Latin America.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/patient-flow-management-solutions-market-730

Key Takeaways of the Patient Flow Management Solutions Market:

The global patient flow management solutions market is expected to exhibit a CAGR of 8% during the forecast period, owing to rising need to manage patient flow in healthcare facilities and to decrease possibility of human error

Among product type, standalone segment accounted for major market share in 2017. Standalone systems are largely preferred, owing to data security concerns among patients and professionals. However, comparatively high cost of maintenance is expected to hinder growth of the standalone segment.

Among component, software segment accounted for the largest share in 2017. Software is an integral and essential part of patient flow management solution system. Patient flow management solution software is used in managing, tracking, and reporting patient data, and are designed for clinics and hospitals that have a huge inflow of patients.

Among delivery mode, web-based/cloud-based segment accounted for the largest share in 2017, as it allows automatic software updates, easy accessibility to information, proper document controlling, and low cost solution as compared to on-premise delivery system.

Among end user, hospital segment accounted for the largest share in 2017, owing to the increasing adoption of patient flow systems to provide structured and consistent care, thereby enabling staffs to provide the best possible care, particularly crucial for patients with dementia or Alzheimer’s disease

Major players operating in the global patient flow management solutions market include Getinge AB, Allscripts Healthcare Solutions, Inc., Cerner Corporation, McKesson Corporation, Epic Systems Corporation, Aptean, Inc., Sonitor Technologies, Inc., Stanley Black & Decker, Inc., and TeleTracking Technologies, Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/730

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Biopreservation Market To Reach US$ 19,748.6 Million By 2027 - Coherent Market Insights

Biopreservation is an important aspect of biobanking. The duration for preservation of biological samples may either short or long-term, depending on the demand for the specific specimen. In order to encourage sample donation for research activities, it is very essential to maintain the functionality and stability of samples throughout their preservation period apart from securing the donor information.

The global Biopreservation Market is estimated to account for US$ 6,646.2 Mn in terms of value in 2020 and is expected to reach US$ 19,748.6 Mn by the end of 2027.

Global Biopreservation Market: Drivers

Increasing prevalence of chronic disorders is expected to propel growth of the global biopreservation market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Global Biopreservation Market: Opportunities

Development of networks for the access of biospecimens and research data is expected to offer lucrative growth opportunities for players in the global biopreservation market. Success in biomedical research can be achieved faster through collaborations and creating networks for the access of biospecimens and research data globally. The implementation of global accessibility model will result in rise in the transnational activity. This in turn will generate demand for media for maintaining sample stability while transporting the biospecimen to a destination.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/748

Global Biopreservation Market: Restraints

Expenses incurred for the maintenance and sustenance of biobanks are a concern for the global biopreservation market. A small biobank requires huge capital to store and process biospecimens throughout the preserving period.

Key Takeaways:

The global biopreservation market was valued at US$ 5,692.8 Mn in 2019 and is forecast to reach a value of US$ 19,748.6 Mn by 2027 at a CAGR of 16.8% between 2020 and 2027. Major factor driving the growth of global biopreservation market during the forecast period include increasing number of biobanks, and emergence of COVID-19.

Equipment held dominant position in the global biopreservation market in 2019, accounting for 82.0% share in terms of value, followed by culture media.

Market Trends

Increasing cell therapy manufacturing activities are expected to propel growth of the global biopreservation market. For instance, in August 2020, IsoPlexis collaborated with Lonza Group under which IsoLight automated proteomics platform will be used for functional quality analytics for products produced on Lonza’s Cocoon automated cell manufacturing system.

However, stringent regulatory scenario for gene therapy is expected to limit adoption for biopreservation in the healthcare sector, thereby hindering growth of the market. For instance, in August 2020, the U.S. Food and Drug Administration rejected a one-time gene therapy for hemophilia A.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/biopreservation-market-748

Global Biopreservation Market: Competitive Landscape

Major players operating in the global biopreservation market include, BioCision, LLC, BioLife Solutions, Inc., Biomatrica, Inc., CHART MVE BIOMEDICAL, Dometic Group, Panasonic Corporation, VWR International, LLC, Thermo Fisher Scientific, Inc., Simport Scientific, ThermoGenesis Holdings, Inc., Atlanta Biologics, Lifeline Scientific, LabVantage Solutions, Inc., Hamilton Company, and Core Dynamics Ltd.

Global Biopreservation Market: Key Developments

Major players in the global biopreservation market are focused on adopting M&A strategies to expand their product portfolio. For instance, in March 2020, Thermo Fisher Scientific Inc. announced to acquire QIAGEN N.V., a provider of molecular diagnostics and sample preparation technologies.

Major players in the market are also focused on R&D of new products to expand their product portfolio. For instance, in July 2018, Biomatrica, Inc. announced the grant of new U.S. patent for the stabilization and storage of nucleic acids and proteins for blood collection.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/748

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-173

Gunshot Injuries Treatment Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

The Global Gunshot Injuries Treatment Market was valued at US$ 6.9 million in 2015 and is projected to exhibit a CAGR of 8.2% over the forecast period (2017–2025). Technological developments such as innovative pocket sized device, which use tiny sponges and emergency treatment in the battlefield for soldiers, are expected to be major factors driving growth of the global gunshot injuries treatment market over the foreseeable future. Efficient treatment by products that prevent postpartum hemorrhage to boost the gunshot injuries treatment market Postpartum hemorrhage (PPH) is the leading cause of maternal mortality in low-income countries, and responsible for a quarter of all maternal deaths globally.

According to an article published by Medscape, pregnancy-related mortality ratio was estimated to be 17.3 deaths per 100,000 pregnant women, with around 11.4% of these deaths caused due by postpartum hemorrhage, in 2013. The initiatives taken by organizations such as the United States Agency for International Development (USAID), the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada, and the UK Government to aid research for the development of preventive devices for PPH is a major factor causing expansion of the gunshot injuries treatment market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/772

Furthermore, the development of the XSTAT-PPH device by Oregon Health & Science Univsersity and RevMedx for the treatment of postpartum hemorrhage (PPH) in low resource settings accelerates growth of the gunshot injuries treatment market.

Surgical priorities for prevention of gunshot management includes hemorrhage control, prevention, and reconstruction of infection, as gunshot has potential to damage affected tissues. The Xstat syringe was the only FDA-approved device for immediate treatment of blood flow. According to an article published in Current Reviews in Musculoskeletal Medicine, in 2015, around 70% of battlefield wounds sustained in conflict since the Second World War were gunshot injuries during the early phases of conflicts. Furthermore, affected soldiers require immediate transfer to trauma center for definitive management for conducting initial care and stabilization in emergency department.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/gunshot-injuries-treatment-market-772

Key takeaways of the Gunshot Injuries Treatment Market:

The global gunshot injuries treatment market is expected to exhibit a CAGR of 8.2% over the forecast period, with economies in Asia Pacific, Latin America, Middle East, and Africa focusing on increasing their military spending.

The Xstat is the dominant product segment in the market, as this portable device provides emergency treatment for soldiers in the battlefield

RevMedx, Inc currently is the only player involved in the global gunshot injuries treatment market.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/772

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Antibiotics and Corticosteroids Market Size, Trends, Shares, Insights and Forecast – 2018-2026

Rising cases of infectious diseases and established healthcare sector is fuelling to the growth of antibiotics and corticosteroids market in North America

Regional segmentation of Antibiotics and Corticosteroids Market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, the Middle East and Africa. North America hold the major share in the antibiotics and corticosteroids market due to the high prevalence rate of respiratory syncytial virus (RSV) infection and the need of antibiotic and corticosteroids treatment of such diseases. For instance, the data given by Centers for Disease Control and Prevention (CDC), around 2.1 million children are diagnosed with RSV and 14, 000 adult population die due to this disease annually. Latin America also hold the large share in the antibiotics and corticosteroids market followed by Asia Pacific due to the progress in pharmaceutical industry.

Antibiotics are used to terminate the bacterial growth or bacteria itself in the case of bacterial infection, whereas, corticosteroids are used to treat the allergy and inflammatory condition. There are some functions which corticosteroids can perform while antibiotics cannot perform and vice-versa. At times, the physician prescribes the dose of antibiotics in addition with corticosteroids so that antibiotic will help attack the microorganism cell wall whereas the inflammatory process can be tackled by the corticosteroids. Corticosteroids also decreases the pain related to inflammation by inhibiting chemical mediators. Over dosage or misuse of both compounds might lead to adverse effects such as failure of immune system.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/781

Efficacy of combine treatment of antibiotics and corticosteroids on several chronic diseases is the major factor for growth of antibiotics and corticosteroids market

The use of antibiotics with the combination of corticosteroids has proven effective in the treatment of human respiratory syncytial virus (hRSV) infection, Cepacia syndrome, S. Aureus arthritis, pneumonia, Zika Virus, and Ebola. According to the data published in Journal of Tropical Diseases and Public Health, in 2016, around 6.3 million children died in 2013, wherein 51.8% died due to infectious diseases and largest was accounted due to pneumonia for around 935,000 deaths. However, around 3.4 million children are infected with the human Respiratory syncytial virus (RSV) which is associated to acute lower respiratory infections (ALRI). Supportive government activities in the favor of antibiotics and corticosteroids production is helping to boost the antibiotic and corticosteroids market. For instance, introduction of Antibiotics Incentives Now (GAIN) act which has the provisions to facilitate the development of therapy against antigen resistant pathogens is expected to propel the approval for antibiotics.

However, some of the restraints which are likely to hamper the growth of antibiotics and corticosteroids market include the adverse effect on high intake or misuse of both antibiotics and corticosteroids, use in animals which are later consumed by humans, and regulations and policies on use of antibiotics and corticosteroids.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/antibiotics-and-corticosteroids-market-781

Rise in population with pneumonia is contributing to the growth of this disease segment in antibiotics and corticosteroids market

Industry players are involved in the regional expansion and collaborations with other companies to hold the larger share in the antibiotics and corticosteroids market

Key industry players operating the global antibiotics and corticosteroids market include Novartis, Pfizer, GlaxoSmithKline (GSK), Abbott Laboratories, Sanofi, Johnson & Johnson, Merck, Sumitomo, AstraZeneca, Cipla, and Astellas Pharma. The generic drug manufacturers are dominating in the antibiotics and corticosteroid market due to the presence of key drugs that are helping to generate the revenue with availability of few patent products. Adoption of various strategies such as regional expansion, novel product development, collaborations, and partnerships by the industry players to hold the major share in the antibiotics and corticosteroids market. For instance, Pfizer made an agreement with AstraZeneca in 2016, which has helped to acquire the commercialization and development right to the Pfizer’s business mostly outside the U.S.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/781

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Analysis-2027

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and Non-stimulants (Atomoxetine, Bupropion, Guanfacine, and Clonidine), by Age Group (Pediatric and Adolescent, and Adult), by Distribution Channel (Specialty Clinics, Hospital Pharmacies, Retail Pharmacies, and E-commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 18,169.0 million in 2020 and is expected to exhibit a CAGR of 7.1 % during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Key companies are focusing on rising approval of new products from the regulatory authority, in order to provide better options for treatment of ADHD in pediatric and adolescent patients, which is expected to bolster market growth over the forecast period. For instance, in August 2018, Ironshore Pharmaceuticals & Development, Inc., a subsidiary of Highland Therapeutics Inc., received the U.S. Food and Drug Administration (FDA) approval for its New Drug Application (NDA) for JORNAY PM (methylphenidate) for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and older.

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market – Impact of Coronavirus (COVID-19)

The COVID-19 pandemic has drastically impacted each and every market across the world. Therefore, government of various countries are taking initiatives to combat attention-deficit hyperactivity disorder (ADHD) amid Covid-19.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/830

In order to manage attention deficit hyperactivity disorder (ADHD) during the COVID-19 pandemic, organizations such as National Resource Center on ADHD (NRC), Children and Adults with Attention-Deficit/ Hyperactivity Disorder (CHADD), and others provide education and support, and spread awareness about attention deficit hyperactivity disorder among the patients suffering from ADHD. Such organizations are funded by government organizations including the Centers for Disease Control and Prevention (CDC). For instance, on July 1, 2020, the Center for Disease Control and Prevention (CDC) highlighted the negative effects of social distancing. They reported that social distancing increased mental stress among the people and it is more evident in ADHD patients, due to which the behavioral problems in some of the ADHD patients have become worse.

Browse 35 Market Data Tables and 38 Figures spread through 181 Pages and in-depth TOC on “Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and Non-stimulants (Atomoxetine, Bupropion, Guanfacine, and Clonidine), by Age Group (Pediatric and Adolescent, and Adult), by Distribution Channel (Specialty Clinics, Hospital Pharmacies, Retail Pharmacies, and E-commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)”

The market is expected to witness significant growth during the forecast period, owing to key players focusing on launch of new ADHD services and formation of new hubs for the diagnosis, assessment, and treatment of ADHD. For instance, in September 2020, Nottinghamshire Healthcare announced the launch of attention deficit hyperactivity disorder (ADHD) service, wherein adults with ADHD in Nottinghamshire can receive the support for diagnostic assessment and the right treatment.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/attention-deficit-hyperactivity-disorder-treatment-market-830

Key Takeaways of the Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market:

The global attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to exhibit a CAGR of 7.1% during the forecast period, owing to key companies focusing on product launches and approval for the treatment of attention deficit hyperactivity disorder (ADHD)

Among drug type, stimulants segment is expected to hold major market share in the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period, owing to an increasing number of launch of new products for the treatment of patients with ADHD by key companies

Among age group, adults segment is expected to hold major market share in the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period, owing to increasing prevalence of attention deficit hyperactivity disorder (ADHD) in adult population globally

Among distribution channel, retail pharmacies segment is expected to hold major market share in the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period, owing to increasing number of retail pharmacies & chain stores, easy access of products, and strategic tie-ups between major companies & retail pharmacies

Key players operating in the global attention deficit hyperactivity disorder (ADHD) therapeutics market include Amneal Pharmaceuticals, Inc., Eli Lilly And Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., and Purdue Pharma L.P.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/830

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737